Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B

Asociación Mexicana de Hepatología A.C. Clinical guideline on hepatitis B

Hepatitis B virus (HBV) infection continues to be a worldwide public health problem. In Mexico, at least three million adults are estimated to have acquired hepatitis B (total hepatitis B core antibody [anti-HBc]-positive), and of those, 300,000 active carriers (hepatitis B surface antigen [HBsAg]-p...

Full description

Bibliographic Details
Main Authors:	F. Higuera-de-la-Tijera, G.E. Castro-Narro, J.A. Velarde-Ruiz Velasco, E. Cerda-Reyes, R. Moreno-Alcántar, I. Aiza-Haddad, M. Castillo-Barradas, L.E. Cisneros-Garza, M. Dehesa-Violante, J. Flores-Calderón, M.S. González-Huezo, E. Márquez-Guillén, L.E. Muñóz-Espinosa, J.L. Pérez-Hernández, M.V. Ramos-Gómez, J. Sierra-Madero, J.F. Sánchez-Ávila, A. Torre-Delgadillo, R. Torres, E.R. Marín-López, D. Kershenobich, E. Wolpert-Barraza
Format:	Article
Language:	English
Published:	Elsevier 2021-10-01
Series:	Revista de Gastroenterología de México (English Edition)
Subjects:	Virus de la hepatitis B Hepatitis aguda Hepatitis crónica Antígeno de superficie de hepatitis B Entecavir Tenofovir disoproxil fumarato
Online Access:	http://www.sciencedirect.com/science/article/pii/S2255534X21000918

Similar Items

Asociación Mexicana de Hepatología A.C. Guía Clínica de Hepatitis B
by: F. Higuera-de-la-Tijera, et al.
Published: (2021-10-01)

Entecavir administration to pregnant Japanese woman with chronic hepatitis B and hepatocellular carcinoma: A case report
by: Toshihiko Kakiuchi, et al.
Published: (2021-03-01)

Tenofovir Disoproxil Fumarate Is Superior to Entecavir in Reducing Hepatitis B Surface Antigen for Chronic Hepatitis B in China: 2-Year Comprehensive Comparative Result of a Matched Comparative Study
by: Sisi Yang, et al.
Published: (2021-03-01)

Tenofovir Is Superior to Entecavir on Tertiary Prevention for BCLC Stage 0/A Hepatocellular Carcinoma after Curative Resection
by: Ming-Chao Tsai, et al.
Published: (2021-09-01)

Short-term and long-term safety and efficacy of tenofovir alafenamide, tenofovir disoproxil fumarate and entecavir treatment of acute-on-chronic liver failure associated with hepatitis B
by: Juan Li, et al.
Published: (2021-06-01)

Comparison of first-year results of tenofovir and entecavir treatments of nucleos(t)ide-naive chronic hepatitis B patients with hepatosteatosis
by: Zeynal Dogan, et al.
Published: (2015-01-01)

Evaluation of the Efficacy of Entecavir and Tenofovir in the Treatment of Chronic Hepatitis B: A Retrospective Study
by: Arzu ŞENOL, et al.
Published: (2019-12-01)

Analysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countries
by: Andrew Hill, et al.
Published: (2015-04-01)

Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir
by: Nobuharu Tamaki, et al.
Published: (2020-06-01)

Resultados en la práctica clínica del tratamiento de la hepatitis crónica por virus B con tenofovir y entecavir
by: Diana Horta, et al.

Prevention of Hepatitis B Virus Reactivation in Kidney Transplant Recipients
by: H Nasri, et al.
Published: (2016-04-01)

The genotoxicity of Tenofovir disoproxil fumarate in HBV-infected patients
by: Selcen Korkmaz, et al.
Published: (2018-09-01)

Renal safety of tenofovir and/or entecavir in patients with chronic HBV monoinfection
by: Yang YM, et al.
Published: (2017-09-01)

Efficacy of different nucleoside analog rescue therapies for entecavir-resistant chronic hepatitis B patients
by: Jin Shang, et al.
Published: (2021-09-01)

Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy
by: Ogawa E, et al.
Published: (2017-11-01)

Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores
by: Chen, L., et al.
Published: (2022)

First-line oral antiviral therapies showed similar efficacies in suppression of serum HBcrAg in chronic hepatitis B patients
by: Lung-Yi Mak, et al.
Published: (2021-03-01)

Compare with safety and efficacy of entecavir and adefovir dipivoxil combination therapy and tenofovir disoproxil fumarate monotherapy for chronic hepatitis B patient with adefovir-resistant
by: Ming-Chun Lai, et al.
Published: (2020-01-01)

Retrospective Evaluation of the Treatment Results of Patients with Chronic Hepatitis B and C Infections
by: Servet Öztürk, et al.
Published: (2020-02-01)

Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?
by: Byoung Kuk Jang
Published: (2020-07-01)

Efficacia e sicurezza di entecavir dopo switch da tenofovir per comparsa di effetti collaterali renali: uno studio multicentrico italiano, di pratica clinica, su 103 pazienti con epatite cronica B
by: Mauro Viganò
Published: (2018-09-01)

Unsuccessful therapy with adefovir and entecavir-tenofovir in a patient with chronic hepatitis B infection with previous resistance to lamivudine: a fourteen-year evolution of hepatitis B virus mutations
by: Tanno Hugo, et al.
Published: (2011-06-01)

Analogs in the treatment of chronic hepatitis B: real life experience with tenofovir and entecavir
by: Rosanna Villani, et al.
Published: (2015-06-01)

Virologic response and safety of tenofovir versus entecavir in treatment-naïve chronic Hepatitis B patients
by: Hyung Min Yu, et al.
Published: (2015-01-01)

Comparable efficacy of tenofovir versus entecavir and predictors of response in treatment-naïve patients with chronic hepatitis B: a multicenter real-life study
by: Ayse Batirel, et al.
Published: (2014-11-01)

Efficacy of tenofovir-based rescue therapy for chronic hepatitis B patients with resistance to lamivudine and entecavir
by: Hee-Jeong Jeon, et al.
Published: (2017-09-01)

Hepatitis B Virus-Related Cryoglobulinemic Vasculitis: Review of the Literature and Long-Term Follow-Up Analysis of 18 Patients Treated with Nucleos(t)ide Analogues from the Italian Study Group of Cryoglobulinemia (GISC)
by: Cesare Mazzaro, et al.
Published: (2021-05-01)

Latest progress in treatment of chronic hepatitis B with tenofovir disoproxil fumarate
by: ZHANG Yue
Published: (2015-04-01)

Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma
by: Sung Won Lee, et al.
Published: (2021-07-01)

Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice
by: José Ángel Cuenca-Gómez, et al.
Published: (2018-11-01)

A comparison between entecavir and tenofovir in chronic hepatitis B in the clinical practice: a single-center experience
by: Salvatore Sollima, et al.
Published: (2015-06-01)

Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B
by: Young Min Kim, et al.
Published: (2018-01-01)

The efficacy of tenofovir-based therapy in patients showing suboptimal response to entecavir-adefovir combination therapy
by: Jeong Han Kim, et al.
Published: (2016-06-01)

Long-term entecavir efficacy retention in the treatment of chronic hepatitis B with an outcome to hepatic cirrhosis caused by its resistant virus strain
by: O O Znoĭko, et al.
Published: (2012-11-01)

The Occurrence of rtA194T Mutant After Long-Term Lamivudine Monotherapy Remains Sensitive to Tenofovir Disoproxil Fumarate: A Case Report
by: Li J, et al.
Published: (2021-03-01)

The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis
by: Zeyu Zhang, et al.
Published: (2019-05-01)

Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy
by: Jung Gil Park, et al.
Published: (2015-09-01)

THE EXPERIENCE OF ENTECAVIR USE IN PATIENTS WITH HEPATITIS B VIRAL INFECTION ON AN OUTPATIENT BASIS
by: L. I. Mel'nikova, et al.
Published: (2016-02-01)

Efficacy of tenofovir alafenamide in treatment of hepatitis B virus: A meta-analysis and non-inferiority evaluation
by: Qiu-Ran Wang, et al.
Published: (2021-06-01)

Experience of entecavir therapy in chronic hepatitis B
by: E. V. Esaulenko, et al.
Published: (2014-09-01)